3SBio Inc. (1530.HK)
HKD 6.11
(-0.49%)
HKD 6.11
(-0.49%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.83 Billion CNY | 8.26% |
| 2022 | 4.46 Billion CNY | 69.98% |
| 2021 | 2.62 Billion CNY | -9.79% |
| 2020 | 2.91 Billion CNY | 3.65% |
| 2019 | 2.81 Billion CNY | -14.67% |
| 2018 | 3.29 Billion CNY | -25.23% |
| 2017 | 4.4 Billion CNY | 44.03% |
| 2016 | 3.05 Billion CNY | 655.34% |
| 2015 | 405 Million CNY | -34.41% |
| 2014 | 617.42 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.16 Billion CNY | 1.12% |
| 2024 Q1 | 4.16 Billion CNY | -13.86% |
| 2023 Q1 | 4.96 Billion CNY | 11.0% |
| 2023 FY | 4.83 Billion CNY | 8.26% |
| 2023 Q4 | 4.83 Billion CNY | 0.2% |
| 2023 Q3 | 4.82 Billion CNY | -2.88% |
| 2023 Q2 | 4.97 Billion CNY | 0.23% |
| 2022 Q4 | 4.46 Billion CNY | -0.84% |
| 2022 FY | 4.46 Billion CNY | 69.98% |
| 2022 Q1 | 3.83 Billion CNY | 45.75% |
| 2022 Q2 | 3.84 Billion CNY | 0.3% |
| 2022 Q3 | 4.5 Billion CNY | 17.26% |
| 2021 FY | 2.62 Billion CNY | -9.79% |
| 2021 Q2 | 2.64 Billion CNY | 0.35% |
| 2021 Q1 | 2.63 Billion CNY | -9.54% |
| 2021 Q3 | 2.61 Billion CNY | -1.02% |
| 2021 Q4 | 2.62 Billion CNY | 0.4% |
| 2020 Q1 | 4.4 Billion CNY | 56.77% |
| 2020 Q2 | 4.41 Billion CNY | 0.17% |
| 2020 Q3 | 2.9 Billion CNY | -34.15% |
| 2020 Q4 | 2.91 Billion CNY | 0.24% |
| 2020 FY | 2.91 Billion CNY | 3.65% |
| 2019 FY | 2.81 Billion CNY | -14.67% |
| 2019 Q1 | 3.68 Billion CNY | 11.83% |
| 2019 Q4 | 2.81 Billion CNY | -2.31% |
| 2019 Q3 | 2.87 Billion CNY | -20.36% |
| 2019 Q2 | 3.61 Billion CNY | -1.92% |
| 2018 Q1 | 3.87 Billion CNY | -12.15% |
| 2018 Q4 | 3.29 Billion CNY | -2.1% |
| 2018 Q3 | 3.36 Billion CNY | -11.5% |
| 2018 Q2 | 3.8 Billion CNY | -1.76% |
| 2018 FY | 3.29 Billion CNY | -25.23% |
| 2017 Q2 | 2.4 Billion CNY | -2.87% |
| 2017 Q3 | 4.47 Billion CNY | 85.83% |
| 2017 Q4 | 4.4 Billion CNY | -1.5% |
| 2017 FY | 4.4 Billion CNY | 44.03% |
| 2017 Q1 | 2.47 Billion CNY | -18.99% |
| 2016 Q1 | 3.54 Billion CNY | 775.25% |
| 2016 FY | 3.05 Billion CNY | 655.34% |
| 2016 Q4 | 3.05 Billion CNY | -3.46% |
| 2016 Q3 | 3.16 Billion CNY | -10.61% |
| 2016 Q2 | 3.54 Billion CNY | 0.0% |
| 2015 Q3 | 405 Million CNY | -39.76% |
| 2015 Q2 | 672.36 Million CNY | 0.0% |
| 2015 Q1 | 672.36 Million CNY | 8.9% |
| 2015 FY | 405 Million CNY | -34.41% |
| 2015 Q4 | 405 Million CNY | 0.0% |
| 2014 FY | 617.42 Million CNY | 0.0% |
| 2014 Q4 | 617.42 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 52.86 Million HKD | -9050.969% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.93 Billion HKD | 18.433% |